SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject4/29/2002 4:00:01 PM
From: pchristi12534   of 508
 
This morning I read through their most recent 10K and was surprised to read management's comment the the combined market for the three primary products undergoing trials was $9 billion. For a company with an annual revenue run rate (as of last quarter) of $53,161,000, the potential market from those three products is very impressive.

Meanwhile, management has demonstrated that they can grow revenues from existing products, quarterly year-over-year and sequentially. They also have done a good job this quarter's full year versus last quarter's full year.

One possible negative is the fact that Fidelity reduced its holdings of ITMN from 11.4% to 7.5% within a span of 4 days - Feb 11th to Feb 15th.
fttp://footprintstocks.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News